ANP presenting now, page-103

Yes.

Plan B is usually same as Plan A but with an element of panic

Sarepta needs to do something to instill confidence in their program.

Their major shareholders would not be happy considering the $$$ pumped into their Gene Therapy IP.

Sarepta’s dwindling market cap now makes them easy pickings for Big Pharma.

Considering their $1.9B cash position - they need to hunt or be hunted.

Best case for all including the DMD boys, is for Sarepta to take the lead in the US for P2B.

$500m upfront for DMD rights in the US will do the trick...I’ll vote yes to that.

Exciting couple of months ahead.
.